老牌中药企业香雪制药陷困境：涉讼金额超九千万，正推动预重整

Core Viewpoint - ST Xiangxue Pharmaceutical Co., Ltd. is facing multiple challenges, including significant legal disputes and ongoing financial losses, which have led to a pre-restructuring process initiated in early 2025 [1][3][4]. Group 1: Legal Issues - The company and its subsidiaries have been involved in lawsuits totaling approximately 92.27 million yuan over the past year, which accounts for 8.78% of the latest audited net assets [1]. - Major legal disputes include a contract dispute with Guangzhou Wanbo Jiacheng Venture Capital involving 20.92 million yuan and a financial loan dispute with Agricultural Bank of China involving 44.96 million yuan [1]. Group 2: Financial Performance - ST Xiangxue has experienced a decline in net profit since 2016, with a significant loss of 677 million yuan in 2021, followed by continued losses of 530 million yuan in 2022, 389 million yuan in 2023, and an expected loss of 859 million yuan in 2024 [2]. - The company anticipates a net profit loss of between 635 million yuan and 934 million yuan for 2025, primarily due to intensified market competition, liquidity issues, and high financial costs [4]. Group 3: Restructuring Process - A pre-restructuring process was initiated in January 2025 after a creditor filed a notice citing the company's inability to repay debts, although the company is considered to have restructuring value [3]. - The pre-restructuring period has been extended multiple times, with the latest extension pushing the deadline to January 11, 2026, but there remains uncertainty regarding whether the company will formally enter the restructuring process [3].